| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |